Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$20.10 USD
+0.07 (0.35%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FLGT 20.10 +0.07(0.35%)
Will FLGT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FLGT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FLGT
Privia Health (PRVA) Misses Q4 Earnings Estimates
Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates
FLGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength?
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
Other News for FLGT
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
What's Driving Twist Bioscience Corp's Surprising 44% Stock Rally?
Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)
Fulgent Genetics price target lowered by $3 at Piper Sandler, here's why
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript